|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 December 2000, Vol. 96, No. 12, pp. 3681-3695
REVIEW ARTICLE
CD30+ anaplastic large cell
lymphoma: a review of its histopathologic, genetic, and
clinical features
Harald Stein,
Hans-Dieter Foss,
Horst Dürkop,
Theresa Marafioti,
Georges Delsol,
Karen Pulford,
Stefano Pileri, and
Brunangelo Falini
From the Institute of Pathology and Consultation and
Reference Center for Lymph Node Pathology and Haematopathology,
University Hospital Benjamin Franklin, Free University, Berlin,
Germany; Laboratoire d' Anatomie et Cytologie Pathologiques,
Hôpital Purpan, Toulouse, France; Nuffield Department of Clinical
Laboratory Sciences, LRF Immunodiagnostics Unit, John Radcliffe
Hospital, University of Oxford, Oxford, England; Servizio di Anatomia
Patologica Sezione di Emolinfopatologia, Università degli Studi
di Bologna, Italy; and Dipartimento di Medicina Clinica e Sperimentale,
Sezione di Ematologia e Immunologia Clinica, Policlinico Monteluce,
Università degli Studi di Perugia, Italy.
Anaplastic large cell lymphoma (ALCL) represents a generally
recognized group of large cell lymphomas. Defining features consist of
a proliferation of predominantly large lymphoid cells with strong
expression of the cytokine receptor CD30 and a characteristic growth
pattern. With the use of molecular and clinical criteria, 3 entities of
ALCL have been identified: primary systemic anaplastic lymphoma kinase
(ALK)+ ALCL, primary systemic ALK ALCL, and
primary cutaneous ALCL. ALK expression is caused by chromosomal
translocations, most commonly t(2;5). ALK+ ALCL
predominantly affects young male patients and, if treated with
chemotherapy, has a favorable prognosis. It shows a broad morphologic
spectrum, with the "common type," the small cell variant, and the
lymphohistiocytic variant being most commonly observed. The knowledge
of the existence of these variants is essential in establishing a
correct diagnosis. ALK ALCL occurs in older patients,
affecting both genders equally and having an unfavorable prognosis. The
morphology and the immunophenotype of primary cutaneous ALCL show an
overlap with that of lymphomatoid papulosis. Both diseases have an
excellent prognosis, and secondary systemic dissemination is only
rarely observed. The described ALCL entities usually derive from
cytotoxic T cells. In contrast, large B-cell lymphomas with anaplastic
morphology are believed to represent not a separate entity but a
morphologic variant of diffuse large B-cell lymphoma. Malignant
lymphomas with morphologic features of both Hodgkin disease and ALCL
have formerly been classified as Hodgkin-like ALCL . Recent
immunohistologic studies, however, suggest that ALCLs
Hodgkin-like represent either cases of tumor cell-rich classic
Hodgkin disease or (less commonly) ALK+ ALCL or
ALK ALCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. P. Mosse, A. Wood, and J. M. Maris
Inhibition of ALK Signaling for Cancer Therapy
Clin. Cancer Res.,
September 15, 2009;
15(18):
5609 - 5614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sozzi, M. P. Martelli, D. Conte, P. Modena, V. Pettirossi, S. A. Pileri, and B. Falini
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues
Haematologica,
September 1, 2009;
94(9):
1307 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and M. P. Martelli
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy
Haematologica,
July 1, 2009;
94(7):
897 - 900.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Cardarelli, M.-C. Moldovan-Loomis, B. Preston, A. Black, D. Passmore, T.-H. Chen, S. Chen, J. Liu, M. R. Kuhne, M. Srinivasan, et al.
In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma
Clin. Cancer Res.,
May 15, 2009;
15(10):
3376 - 3383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, S. Kreher, K. J. Meaburn, K. Johrens, B. Lamprecht, C. Assaf, W. Sterry, M. E. Kadin, M. Daibata, S. Joos, et al.
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma
PNAS,
April 7, 2009;
106(14):
5831 - 5836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Buxton, C. E. Bacchi, G. Gualco, L. M. Weiss, C. W. Zuppan, E. H. Rowsell, Q. Huang, and J. Wang
Frequent Expression of CD99 in Anaplastic Large Cell Lymphoma: A Clinicopathologic and Immunohistochemical Study of 160 Cases
Am J Clin Pathol,
April 1, 2009;
131(4):
574 - 579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, et al.
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
Am. J. Pathol.,
February 1, 2009;
174(2):
661 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe, N. L. Harris, H. Stein, and P. G. Isaacson
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
Blood,
December 1, 2008;
112(12):
4384 - 4399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Bartlett, A. Younes, M. H. Carabasi, A. Forero, J. D. Rosenblatt, J. P. Leonard, S. H. Bernstein, R. G. Bociek, J. M. Lorenz, B. W. Hart, et al.
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Blood,
February 15, 2008;
111(4):
1848 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. de Leval and P. Gaulard
Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas
Hematology,
January 1, 2008;
2008(1):
272 - 279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al.
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Blood,
November 1, 2007;
110(9):
3374 - 3383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. Wu, M. Yao, H.-F. Tien, J.-L. Tang, C.-W. Lin, and Y.-C. Chen
Anaplastic Large Cell Lymphoma in Leukemic Transformation: Successful Treatment by Transplantation
J. Clin. Oncol.,
October 1, 2007;
25(28):
4490 - 4492.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2259 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Galietta, R. H. Gunby, S. Redaelli, P. Stano, C. Carniti, A. Bachi, P. W. Tucker, C. J. Tartari, C.-J. Huang, E. Colombo, et al.
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2600 - 2609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Damm-Welk, K. Busch, B. Burkhardt, J. Schieferstein, S. Viehmann, I. Oschlies, W. Klapper, M. Zimmermann, J. Harbott, A. Reiter, et al.
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma
Blood,
July 15, 2007;
110(2):
670 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell, S. M. Horwitz, A. Engert, K. D. Khan, T. Lin, R. Strair, T. Keler, R. Graziano, D. Blanset, M. Yellin, et al.
Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
J. Clin. Oncol.,
July 1, 2007;
25(19):
2764 - 2769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. de Leval, D. S. Rickman, C. Thielen, A. d. Reynies, Y.-L. Huang, G. Delsol, L. Lamant, K. Leroy, J. Briere, T. Molina, et al.
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells
Blood,
June 1, 2007;
109(11):
4952 - 4963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias
Haematologica,
April 1, 2007;
92(4):
519 - 532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lamant, A. d. Reynies, M.-M. Duplantier, D. S. Rickman, F. Sabourdy, S. Giuriato, L. Brugieres, P. Gaulard, E. Espinos, and G. Delsol
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
Blood,
March 1, 2007;
109(5):
2156 - 2164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A S-Y Leong and T Y-M Leong
Newer developments in immunohistology.
J. Clin. Pathol.,
November 1, 2006;
59(11):
1117 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Y.-Y. Hsu, P. B. Johnston, K. A. Burke, and Y. Zhao
The Expression of CD30 in Anaplastic Large Cell Lymphoma Is Regulated by Nucleophosmin-Anaplastic Lymphoma Kinase-Mediated JunB Level in a Cell Type-Specific Manner.
Cancer Res.,
September 15, 2006;
66(18):
9002 - 9008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Quintanilla-Martinez, S. Pittaluga, C. Miething, M. Klier, M. Rudelius, T. Davies-Hill, N. Anastasov, A. Martinez, A. Vivero, J. Duyster, et al.
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma
Blood,
September 15, 2006;
108(6):
2029 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, and T. A. Waldmann
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Blood,
July 15, 2006;
108(2):
705 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Janz, M. Hummel, M. Truss, B. Wollert-Wulf, S. Mathas, K. Johrens, C. Hagemeier, K. Bommert, H. Stein, B. Dorken, et al.
Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells
Blood,
March 15, 2006;
107(6):
2536 - 2539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood,
February 15, 2006;
107(4):
1255 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al.
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
Blood,
January 15, 2006;
107(2):
689 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, K. Johrens, S. Joos, A. Lietz, F. Hummel, M. Janz, F. Jundt, I. Anagnostopoulos, K. Bommert, P. Lichter, et al.
Elevated NF-{kappa}B p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas
Blood,
December 15, 2005;
106(13):
4287 - 4293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Murphy, P. O'Neill, F. O'Brien, H. Enright, M. Jeffers, J. A. Thornhill, and B. M. Loftus
Anaplastic Large Cell Lymphoma: A Unique Presentation with Urinary Bladder Involvement: A Case Report
International Journal of Surgical Pathology,
October 1, 2005;
13(4):
369 - 374.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Watanabe, M. Sasaki, K. Itoh, M. Higashihara, K. Umezawa, M. E. Kadin, L. J. Abraham, T. Watanabe, and R. Horie
JunB Induced by Constitutive CD30-Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinase Signaling Activates the CD30 Promoter in Anaplastic Large Cell Lymphoma and Reed-Sternberg Cells of Hodgkin Lymphoma
Cancer Res.,
September 1, 2005;
65(17):
7628 - 7634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Jundt, N. Raetzel, C. Muller, C. F. Calkhoven, K. Kley, S. Mathas, A. Lietz, A. Leutz, and B. Dorken
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas
Blood,
September 1, 2005;
106(5):
1801 - 1807.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schnell, M. Dietlein, J. O. Staak, P. Borchmann, K. Schomaecker, T. Fischer, W. Eschner, H. Hansen, F. Morschhauser, H. Schicha, et al.
Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody
J. Clin. Oncol.,
July 20, 2005;
23(21):
4669 - 4678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Kocjan
BEST PRACTICE No 185 Cytological and molecular diagnosis of lymphoma
J. Clin. Pathol.,
June 1, 2005;
58(6):
561 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Rust, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, et al.
High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma
J. Clin. Pathol.,
May 1, 2005;
58(5):
520 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S M Winhoven, S Murugesan, and I H Coulson
Solitary CD30+ anaplastic large cell lymphoma of the eyelid showing regression
Br J Ophthalmol,
March 1, 2005;
89(3):
385 - 385.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Janik, J. C. Morris, S. Pittaluga, K. McDonald, M. Raffeld, E. S. Jaffe, N. Grant, M. Gutierrez, T. A. Waldmann, and W. H. Wilson
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma
Blood,
November 15, 2004;
104(10):
3355 - 3357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Lauder, H. E. Jolin, P. Smith, J. G. van den Berg, A. Jones, W. Wisden, K. G. C. Smith, A. Dasvarma, P. G. Fallon, and A. N. J. McKenzie
Lymphomagenesis, Hydronephrosis, and Autoantibodies Result from Dysregulation of IL-9 and Are Differentially Dependent on Th2 Cytokines
J. Immunol.,
July 1, 2004;
173(1):
113 - 122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zettl, T. Rudiger, M.-A. Konrad, A. Chott, I. Simonitsch-Klupp, R. Sonnen, H. K. Muller-Hermelink, and G. Ott
Genomic Profiling of Peripheral T-Cell Lymphoma, Unspecified, and Anaplastic Large T-Cell Lymphoma Delineates Novel Recurrent Chromosomal Alterations
Am. J. Pathol.,
May 1, 2004;
164(5):
1837 - 1848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
CD30+ Cutaneous Lymphoma in Association With Atopic Eczema
Arch Dermatol,
April 1, 2004;
140(4):
449 - 454.
|
|
|
|
|
|
|
P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al.
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
Blood,
November 15, 2003;
102(10):
3737 - 3742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Morris
ALK in NHL: To B (cell) or not to B (cell)? Characterization of the entity "ALK+ DLBCL"
Blood,
October 1, 2003;
102(7):
2316 - 2317.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, V. S. Lestou, N. L. Harris, H.-K. Muller-Hermelink, J. F. Seymour, L. J. Campbell, D. E. Horsman, I. Auvigne, et al.
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
Blood,
October 1, 2003;
102(7):
2568 - 2573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. De Paepe, M. Baens, H. van Krieken, B. Verhasselt, M. Stul, A. Simons, B. Poppe, G. Laureys, P. Brons, P. Vandenberghe, et al.
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma
Blood,
October 1, 2003;
102(7):
2638 - 2641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onciu, F. G. Behm, J. R. Downing, S. A. Shurtleff, S. C. Raimondi, Z. Ma, S. W. Morris, W. Kennedy, S. C. Jones, and J. T. Sandlund
ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases
Blood,
October 1, 2003;
102(7):
2642 - 2644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol.,
September 15, 2003;
21(18):
3526 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis, M. A. Yared, P. Tsioli, V. Leventaki, A. Schmitt-Graeff, M. Herling, H. M. Amin, and R. Lai
Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK+ and ALK- Anaplastic Large Cell Lymphoma
Clin. Cancer Res.,
September 1, 2003;
9(10):
3692 - 3699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Pruritic Plaque in a 46-Year-Old Woman--Diagnosis
Arch Dermatol,
August 1, 2003;
139(8):
1075 - 1080.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Clarke, E. Legodi, V. Chrystal, and D. Govender
Systemic Anaplastic Large Cell Lymphoma Presenting With Conjunctival Involvement
Arch Ophthalmol,
April 1, 2003;
121(4):
568 - 570.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nishikori, Y. Maesako, C. Ueda, M. Kurata, T. Uchiyama, and H. Ohno
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease
Blood,
April 1, 2003;
101(7):
2789 - 2796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chiarle, J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, et al.
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
Blood,
March 1, 2003;
101(5):
1919 - 1927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, M. Talpaz, and Z. Estrov
Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies
Clin. Cancer Res.,
February 1, 2003;
9(2):
535 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S A Pileri, E Sabattini, S Ascani, P L Zinzani, and B Falini
How do we define Hodgkin's disease? The authors' reply
J. Clin. Pathol.,
February 1, 2003;
56(2):
159 - 159.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ponzoni, M. R. Terreni, F. Ciceri, A. J. M. Ferreri, S. Gerevini, N. Anzalone, M. Valle, S. Pizzolito, and G. Arrigoni
Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants
Ann. Onc.,
November 1, 2002;
13(11):
1827 - 1832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zettl, G. Ott, A. Makulik, T. Katzenberger, P. Starostik, T. Eichler, B. Puppe, M. Bentz, H. K. Muller-Hermelink, and A. Chott
Chromosomal Gains at 9q Characterize Enteropathy-Type T-Cell Lymphoma
Am. J. Pathol.,
November 1, 2002;
161(5):
1635 - 1645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hernandez, S. Bea, B. Bellosillo, M. Pinyol, B. Falini, A. Carbone, G. Ott, A. Rosenwald, A. Fernandez, K. Pulford, et al.
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas : Identification of a New TFG-ALKXL Chimeric Gene with Transforming Activity
Am. J. Pathol.,
April 1, 2002;
160(4):
1487 - 1494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bonvini, T. Gastaldi, B. Falini, and A. Rosolen
Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30+ Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-demethoxygeldanamycin
Cancer Res.,
March 1, 2002;
62(5):
1559 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Turturro, M. D. Arnold, A. Y. Frist, and K. Pulford
Model of Inhibition of the NPM-ALK Kinase Activity by Herbimycin A
Clin. Cancer Res.,
January 1, 2002;
8(1):
240 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Vinante, A. Rigo, M. T. Scupoli, and G. Pizzolo
CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540
Blood,
January 1, 2002;
99(1):
52 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Meech, L. McGavran, L. F. Odom, X. Liang, L. Meltesen, J. Gump, Q. Wei, S. Carlsen, and S. P. Hunger
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion
Blood,
August 15, 2001;
98(4):
1209 - 1216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, M. Seto, S. Nakamura, A. Nakagawa, K. Hara, and K. Takeuchi
Sarcomatoid Variant of Anaplastic Large Cell Lymphoma with Cytoplasmic ALK and {{alpha}}-Smooth Muscle Actin Expression: A Mimic of Inflammatory Myofibroblastic Tumor
Am. J. Pathol.,
July 1, 2001;
159(1):
383 - 384.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Villalva, F. Bougrine, G. Delsol, and P. Brousset
Bcl-2 Expression in Anaplastic Large Cell Lymphoma
Am. J. Pathol.,
May 1, 2001;
158(5):
1889 - 1890.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
